Antiretroviral therapy for patients with HIV disease

British Journal of Clinical Pharmacology

Volumn 45, Issue 3, 1998, Pages 221-228

  Barry, M ^a   Mulcahy, F ^b   Back, D J ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CELL COUNT; DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MORTALITY; OPPORTUNISTIC INFECTION; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; HIV; HIV INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; VIRAL LOAD; VIRUS REPLICATION;

EID: 0031892546     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00673.x     Document Type: Review

References (56)

1. Feinberg M. Changing the natural history of HIV disease. Lancet 1996; 348: 239-246.
2. Saag MS, Holodniy M, Kuritzkes DR, et al. HIV viral load markers in clinical practice. Nature Med. 1996; 2: 625-629.
3. Bartlett JG. Protease inhibitors for HIV infection. Ann Intern Med 1996; 124: 1086-1088.
4. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200-500 per cubic millimeter. N Engl J Med 1996; 335: 1081-1090.
5. Delta Coordinating Committee. DELTA: a randomised double blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996; 348: 283-291.
6. Caesar Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-1421.
7. Hogg RS, O'Shaughnessy MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349: 1294.
8. Torres RA, Barr M. Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997; 336: 1531-1532.
9. Enger C, Graham N, Peng Y, et al. Survival from early, intermediate and late stages of HIV infection. JAMA 1996; 275: 1329-1334.
10. Stein DS, Korvick JA, Vermund SH. CD4+lymphocyte cell enumeration for prediction of clinical course of human immunodeficiency virus disease: a review. J Infect Dis 1992; 165: 352-363.
11. Haynes BF, Panteleo G, Fauci AS. Toward an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271: 324-328.
12. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373: 123-126.
13. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-122.
14. Piatak M, Saag M, Yang L, et al. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993; 259: 1749-1754.
15. Mellors JW, Kingsley LA, Rinaldo CR, Hoo BS, Kookka RP, Gupta P. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 112: 573-579.
16. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-1170.
17. Barry MG, Back DJ, Breckenridge AM. Zidovudine therapy in HIV infection: which patients should be treated and when. Br J Clin Pharmacol 1995; 40: 107-110.
18. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretoviral therapy for HIV infection in 1996. JAMA 1996; 276: 146-154.
19. BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1086-1092.
20. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. JAMA 1997; 277: 1962-1969.
21. Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8: F1-5.
22. D'Aquila RT, Hughes MD, Johnson VA, et al. Nevirapine. zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo, controlled trial. Ann Intern Med 1996; 124: 1019-1030.
23. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review fir clinicians. JAMA 1997; 277: 145-153.
24. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retrovir 1992; 8: 153-164.
25. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. N Engl J Med 1987; 317: 185-191.
26. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731-1734.
27. Johnson VA, Merrill DP, Videler JA, et al. Two drug combinations of zidovudine, didanosine and recombinant interferon-alpha A inhibit replication of zidovudine resistant human immunodeficiency virus type 1 synerstically in vitro. J Infect Dis 1991; 164: 646-655.
28. Collier AC, Coombs RW, Fischl MA, et al. Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med 1993; 119: 786-793.
29. Yarchoan R, Lietzau JA, Nguyen BY, et al. A randomised pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994; 169: 9-17.
30. Choo V. Combination superior to zidovudine in Delta trial. Lancet 1995; 346: 895.
31. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV infected patient with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med 1996; 335: 1099-1106.
32. Phillips AN, Aron JJ, Bartlett JA. HIV-1 RNA levels and the development of clinical disease. AIDS 1996; 10: 859-865.
33. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV infected adults with 200-500 CD4 cells per cubic millimeter. N Egnl J Med 1996; 335: 1091-1098.
34. Markowitz M, Saag M, Powderley WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease to treat HIV-1 infection. N Engl J Med 1995; 333: 1534-1539.
35. Cameron DW, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir, update. XI International Conference on AIDS. Vancouver July 7-12, 1996 (abstract Mo. B. 411).
36. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996; 334: 1011-1017.
37. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337: 734-739.
38. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 210 per cubic millimeter or less. N Engl J Med 1997; 337: 725-733.
39. Veal GJ, Barry M, Khoo S, Back DJ. In vitro screening of nucleoside analog combinations for potential use in anti HIV therapy. AIDS Res Hum Retro 1997; 13: 481-484.
40. Acosta EP, Page LM, Fletcher CV. Clinical Pharmacokinetics of Zidovudine. Clin Pharmacokinet 1996; 30: 251-262.
41. Lea AP, Faulds D, Stavudine: A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs 1996; 51: 846-864.
42. Kozal MJ, Shafer RW, Winters MA, et al. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine treated patients. J Acquir Immune Defic Syndr 1994; 7: 832-838.
43. Moylec GJ. Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combination and sequences. Drugs 1996; 52: 168-185.
44. Denisi R, Bicart See A, Izopet J, et al. STADI STUDY: Once daily administration of didanosine in combination with stavudine in naïve adults. IV European Conference on Clinical Aspects and Treatment of HIV Infection, Hamburg, Germany, 1997, Oct 11-15. [abstract No. 253].
45. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients with HIV disease: Clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997; 32: 194-209.
46. Lloyd J, Carey P, Timmins D, et al. Trough plasma saquinavr level in HIV politive patient. VI European Conference on Clinical Aspects and Treatment of HIV, Hamburg, Germany, 1997, 1997, Oct 11-15. Infection [abstract No. 461].
47. De Cock KM. Guidelines for managing HIV infection. Br Med J 1977; 315: 1-2.
48. Mulcahy F, Ryan M, Merry C, et al. Tolerability of the protease inhibitors. VI Eurpean Conference on Clinical Aspects and Treatment of HIV infection, Hamburg, Germany, 1997, Oct 11-15. [abstract No. 447].
49. Ouellet D, Hsu A, Granneman GR, et al. Assessment of the pharmacokinetic interaction between ritonavir and clarithomycin (abstract PI 58). Clin Pharmacol Ther 1996; 59: 143.
50. Ouellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinylestradiol in healthy female volunteers. XI International Conference on AIDS; 1996 July 9-12: Vancouver, [abstract MoB 1198].
51. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996; 51: 701-712.
52. Murphy RL, Montaner J. Nevirapine: a review of it development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996; 5: 1183-1199.
53. Cheng CL, Smith DE, Carver PL, et al. Steady state pharmacokinetics of delavirdine in HIV-positive patients: Effect on erythromycin breath test. Clin Pharmacol Ther 1997; 61: 531-543.
54. Schmit, J-C., Ruiz L, Clotet B, et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996; 10: 995-999.
55. Eagling V, Back DJ, Barry M. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br. J Clin Pharmacol 1997; 44: 190-194.
56. Merry C, Barry M, Mulcahy F, et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patient. AIDS 1997; 11: F29-33.